JP2021517454A5 - - Google Patents

Info

Publication number
JP2021517454A5
JP2021517454A5 JP2020541437A JP2020541437A JP2021517454A5 JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5 JP 2020541437 A JP2020541437 A JP 2020541437A JP 2020541437 A JP2020541437 A JP 2020541437A JP 2021517454 A5 JP2021517454 A5 JP 2021517454A5
Authority
JP
Japan
Prior art keywords
immune cells
arginase
cells
immune
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020541437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517454A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/051806 external-priority patent/WO2019145453A1/en
Publication of JP2021517454A publication Critical patent/JP2021517454A/ja
Publication of JP2021517454A5 publication Critical patent/JP2021517454A5/ja
Pending legal-status Critical Current

Links

JP2020541437A 2018-01-28 2019-01-24 癌治療のためのアルギナーゼ抑制 Pending JP2021517454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153782 2018-01-28
EP18153782.0 2018-01-28
PCT/EP2019/051806 WO2019145453A1 (en) 2018-01-28 2019-01-24 Arginase suppression for cancer treatment

Publications (2)

Publication Number Publication Date
JP2021517454A JP2021517454A (ja) 2021-07-26
JP2021517454A5 true JP2021517454A5 (cg-RX-API-DMAC7.html) 2022-02-24

Family

ID=61074351

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020541437A Pending JP2021517454A (ja) 2018-01-28 2019-01-24 癌治療のためのアルギナーゼ抑制

Country Status (7)

Country Link
US (1) US20210177897A1 (cg-RX-API-DMAC7.html)
EP (1) EP3743510A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021517454A (cg-RX-API-DMAC7.html)
CN (1) CN111902532A (cg-RX-API-DMAC7.html)
AU (1) AU2019211067A1 (cg-RX-API-DMAC7.html)
CA (1) CA3125797A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019145453A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL417066A1 (pl) 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2431080A1 (en) * 2003-06-02 2004-12-02 Catherine Adele O'brien Enhancement of anticancer immunity through inhibition of arginase
WO2007111626A2 (en) 2006-03-23 2007-10-04 The Johns Hopkins University Arginase ii: a target for the prevention and treatment of atherosclerosis
MX2009005370A (es) 2006-11-21 2009-10-16 Univ Groningen Uso de inhibidores de arginasa en el tratamiento de asma y rinitis alergica.
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
WO2014059248A1 (en) * 2012-10-12 2014-04-17 Philadelphia Health & Education Corporation D/B/A/ Drexel Mir-155 enhancement of cd8+ t cell immunity
WO2014066137A1 (en) * 2012-10-22 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for enhancing cancer immunotherapy
EP3137103B1 (en) 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Methods and compositions for modulating the immune system with arginase i
WO2016187459A1 (en) 2015-05-20 2016-11-24 The Regents Of The University Of California Method for generating human dendritic cells for immunotherapy
KR102929174B1 (ko) 2015-10-30 2026-02-20 더 리전츠 오브 더 유니버시티 오브 캘리포니아 줄기세포로부터 t-세포를 생산하는 방법 및 상기 t-세포를 이용한 면역치료 방법
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies

Similar Documents

Publication Publication Date Title
Patel et al. From concept to cure: The evolution of CAR-T cell therapy
Rui et al. Cancer immunotherapies: advances and bottlenecks
JP7755890B2 (ja) Car発現ベクター及びcar発現t細胞
US20260055157A1 (en) Methods of making chimeric antigen receptor-expressing cells
Bielamowicz et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma
US20210338729A1 (en) CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF
JP2024008968A (ja) 複数の抗原を標的とするcompoundキメラ抗原受容体(cCAR)の組成物およびその使用方法
CN114761037A (zh) 结合bcma和cd19的嵌合抗原受体及其用途
Iwamura et al. siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
US20190255108A1 (en) Chimeric antigen receptor (car) targeting multiple antigens, compositions and methods of use thereof
US20210069241A1 (en) Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
Testa et al. CAR-T cell therapy in B-cell acute lymphoblastic leukemia
EP3490590A2 (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
Hu et al. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
KR20200137030A (ko) 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터
CN106574272A (zh) 靶向多样的多种抗原的通用嵌合抗原受体表达性免疫细胞及其制造方法及其在癌症、感染和自身免疫病的治疗中的应用
US20230226181A1 (en) GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY
WO2022037562A1 (en) Engineered immunoresponsive cells and uses thereof
Chen et al. Natural killer cells: the next wave in cancer immunotherapy
Yu et al. Revolution of CAR engineering for next-generation immunotherapy in solid tumors
JP2025518033A (ja) 免疫細胞クリスパースクリーニングのための方法及び組成物
JP2025513626A (ja) Ciita遺伝子がノックアウトされた操作された免疫細胞及びその用途
Chen et al. Innovative gene engineering strategies to address tumor antigen escape in cell therapy
Cortés-Hernández et al. Chimeric antigen receptor (CAR) T cell therapy for cancer. Challenges and opportunities: An overview
KR20260070126A (ko) Car t 세포의 기능성을 향상시키기 위한 il-2 변이체를 함유하는 car-인게이저